cytokine elimination as rescue therapy in refractory shock due to sepsis or SIRS

• Conditions: R57.2; R65.9; Septic shock; Systemic Inflammatory Response Syndrome, unspecified

• Registration Number: DRKS00005149
• Lead Sponsor: CytoSorbents

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-07-17
• Study Completion: 2015-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Sepsis or SIRS with refractory shock after 4-6 h guideline-based early goal directed therapy

Exclusion Criteria

- age < 18 years
- IL 6 < 1000 pg/ml
- infection with methicillin-resistant staphylococci
- infection with vancomycin-resistant enterococci
- maximal therapy not indicated (e.g.: limited prognosis due to chronical illness)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change of norepinephrine dose 6 and 12 h after start of Cytosorb(R) compared to the dose at the timepoint of start.

Secondary Outcome Measures

Name	Time	Method
Organfunctions (SOFA-score), clearance of lactate, vasopressor dependency index